Abstract
There is a long presymptomatic period during which a person may have biomarker evidence of Alzheimer’s disease (AD) pathophysiology but still be cognitively intact. It is yet unclear which additional factors that ultimately will determine progression to mild cognitive impairment and eventually to AD dementia. Amyloid-β (Aβ) and tau imaging reveal in vivo the key protein aggregates seen in the AD brain and will help in early diagnosis. However, a considerable proportion of elderly individuals are Aβ PET positive while being cognitively intact. With FDG PET, a typical pattern of hypometabolism can be found in both AD and FTD, which reflects the disease progression and can be used to aid in the differential diagnostics. Moreover, tau, neurotransmitter, and neuroinflammation ligands help to understand the pathophysiology of AD, but further studies are needed to understand how they can be applied in the diagnostic process. Which combination of these biomarkers that eventually will turn out to be the most sensitive and best predictor of AD remains to be determined.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239–259
Braak H, Braak E (1997) (1997). Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18(4):351–357
Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800
Jack CR Jr, Knopman DS, Jagust WJ et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12(2):207–216
Choi SH, Kim YH, Hebisch M et al (2014) A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature 515(7526):274–278
Herholz K (2003) PET studies in dementia. Ann Nucl Med 17:79–89
Mielke R, Kessler J, Szelies B et al (1998) Normal and pathological aging—findings of positron-emission-tomography. J Neural Transm 105:821–837
Rocher AB, Chapon F, Blaizot X et al (2004) Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 20:1894–1898
Minoshima S, Giordani B, Berent S et al (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42:85–94
De Santi S, de Leon MJ, Rusinek H et al (2001) Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22:529–539
Nestor PJ, Fryer TD, Smielewski P, Hodges JR (2003) Limbic hypometabolism in Alzheimer’s disease and mild cognitive impairment. Ann Neurol 54:343–351
Mosconi L, Tsui WH, Herholz K et al (2008) Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med 49(3):390–398
de Leon MJ, Convit A, Wolf OT et al (2001) Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 98(19):10966–10971
Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32:486–510
Li Y, Rinne JO, Mosconi L et al (2008) Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 35(12):2169–2181
Reiman EM, Caselli RJ, Yun LS et al (1996) Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334(12):752–758
Small GW, Ercoli LM, Silverman DH et al (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A 97(11):6037–6042
Mosconi L, Rinne JO, Tsui WH et al (2013) Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer’s parents. Neurobiol Aging 34(1):22–34
Jagust W, Gitcho A, Sun F et al (2006) Brain imaging evidence of Alzheimer’s disease in normal aging. Ann Neurol 59:673–681
Silverman DHS, Small GW, Chang CY et al (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286:2120–2127
Santens P, De Bleecker J, Goethals P et al (2001) Differential regional cerebral uptake of 18F-fluoro-2-deoxy-D-glucose in Alzheimer’s disease and frontotemporal dementia at initial diagnosis. Eur Neurol 45:19–27
Foster NL, Heidebrink JL, Clark CM et al (2007) FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain 130(Pt 10):2616–2635
Minoshima S, Foster NL, Sima AA et al (2001) Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 50:358–365
Albin RL, Minoshima S, DAmato CJ et al (1996) Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 47:462–466
Higuchi M, Tashiro M, Arai H et al (2000) Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 162:247–256
Ishii K, Imamura T, Sasaki M et al (1998) Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology 51:125–130
Barber R, Ballard C, McKeith IG, Gholkar A, O’Brien JT (2000) MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 54:1304–1309
Szelies B, Mielke R, Herholz K, Heiss W-D (1994) Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia. Electroencephalogr Clin Neurophysiol 91:131–139
Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 289(1-2):18–22. doi:10.1016/j.jns.2009.08.034
Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20(2):190–199
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844. doi:10.1002/mds.21956
Jokinen P, Scheinin N, Aalto S et al (2010) [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson’s disease with and without dementia. Parkinsonism Relat Disord 16(10):666–670
Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS (2010) Cerebral glucose metabolism of Parkinson’s disease patients with mild cognitive impairment. Eur Neurol 64(2):65–73. doi:10.1159/000315036
Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, Kuhl DE (2011) Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 52(6):848–855. doi:10.2967/jnumed.111.089946
Edison P, Ahmed I, Fan Z et al (2013) Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacology 38(6):938–949. doi:10.1038/npp.2012.255
Garcia-Garcia D, Clavero P, Gasca Salas C et al (2012) Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson’s disease. Eur J Nucl Med Mol Imaging 39(11):1767–1777
Iyo M, Namba H, Fukushi K et al (1997) Measurement of acetylcholinesterase by positron emission tomography in the brain of healthy controls and patients with Alzheimer’s disease. Lancet 349:1805–1809
Kuhl DE, Koeppe RA, Minoshima S et al (1999) In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease. Neurology 52:691–699
Rinne JO, Kaasinen V, Järvenpää T et al (2003) Brain acetycholinesterase activity in mild cognitive impairment and early Alzheimer’s disease. J Neurol Neurosurg Psychiatry 74:113–115
Bohnen NI, Kaufer DI, Ivanco L et al (2003) Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer’s Disease: an in vivo PET Study. Arch Neurol 60:1745–1748
Francis PT, Webster MT, Chessell IP et al (1993) Neurotransmitters and second messengers in aging and Alzheimer’s disease. Ann N Y Acad Sci 695:19–26
Xu Y, Yan J, Zhou P et al (2012) Neurotransmitter receptors and cognitive dysfunction in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol 97(1):1–13. doi:10.1016/j.pneurobio.2012.02.002
Lanari A, Amenta F, Silvestrelli G, Tomassoni D, Parnetti L (2006) Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer’s disease. Mech Ageing Dev 127(2):158–165
Booij J, Habraken JB, Bergmans P et al (1998) Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med 39(11):1879–1884
Rinne JO, Nurmi E, Ruottinen HM et al (2001) [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson’s disease. Synapse 40(3):193–200
Walker Z, Jaros E, Walker RW et al (2007) Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78(11):1176–1181
Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA (2008) Differentiating Alzheimer’s disease from dementia with Lewy bodies and Parkinson’s disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 4(1 Suppl 1):S67–S76. doi:10.1016/j.jalz.2007.11.016
McKeith I, O’Brien J, Walker Z et al (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6:305–313
Walker Z, Costa DC, Walker RWH et al (2002) Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73:134–140
Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 55:306–319
Mintun MA, Larossa GN, Sheline YI et al (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446–452
Rowe CC, Ng S, Ackermann U et al (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68:1718–1725
Engler H, Forsberg A, Almkvist O et al (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 129(Pt 11):2856–2866
Jack CR Jr, Lowe VJ, Weigand SD et al (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132(Pt 5):1355–1365
Scheinin NM, Aalto S, Koikkalainen J et al (2009) Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 73(15):1186–1192
Grimmer T, Tholen S, Yousefi BH et al (2010) Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease. Biol Psychiatry 68(10):879–884
Villemagne VL, Pike KE, Chételat G et al (2011) Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 69(1):181–192
Kemppainen NM, Aalto S, Wilson IA et al (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68(19):1603–1606
Forsberg A, Engler H, Almkvist O et al (2008) PET imaging of amyloid deposits in patients with mild cognitive impairment. Neurobiol Aging 29:1456–1465
Wolk DA, Price JC, Saxton JA et al (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65(5):557–568. doi:10.1002/ana.21598
Nordberg A, Carter SF, Rinne J et al (2013) A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 40:104–114
Okello A, Koivunen J, Edison P et al (2009) Conversion of amyloid positive and negative MCI to AD over 3 years. An 11C-PIB PET study. Neurology 73(10):754–760
Pike KE, Savage G, Villemagne VL et al (2007) Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain 130:2837–2844
Villain N, Chetelat G, Grassiot B et al (2012) Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB-PET longitudinal study. Brain 135(Pt 7):2126–2139
Rowe CC, Ellis KA, Rimajova M et al (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31:1275–1283
Scheinin NM, Wikman K, Jula A et al (2014) Cortical 11C-PIB uptake is associated with age, APOE genotype, and gender in "healthy aging". J Alzheimers Dis 41(1):193–202
Jansen WJ, Ossenkoppele R, Knol DL et al (2015) Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313(19):1924–1938. doi:10.1001/jama.2015.4668
Joshi AD, Pontecorvo MJ, Clark CM et al (2012) Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med 53:378–384
Rowe CC, Ackerman U, Browne W et al (2008) Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7:129–135
Vandenberghe R, Van Laere K, Ivanoiu A et al (2010) 18F-Flutemetamol Amyloid Imaging in Alzheimer Disease and Mild Cognitive Impairment A Phase 2 Trial. Ann Neurol 68:319–329
Rowe CC, Pejoska S, Mulligan RS et al (2013) (2013) Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia. J Nucl Med 54(6):880–886. doi:10.2967/jnumed.112.114785
Cselényi Z, Jönhagen ME, Forsberg A et al (2012) Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med 53(3):415–424. doi:10.2967/jnumed.111.094029
Shoghi-Jadid K, Small GW, Agdeppa ED et al (2002) (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatr 10:24–35
Small GW, Kepe V, Ercoli LM et al (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652–2663
Shin J, Kepe V, Barrio JR, Small GW (2011) The merits of FDDNP-PET imaging in Alzheimer’s disease. J Alzheimers Dis 26(Suppl 3):135–145
Zwan MD, Okamura N, Fodero-Tavoletti MT et al (2014) Voyage au bout de la nuit: Aβ and tau imaging in dementias. Q J Nucl Med Mol Imaging 58(4):398–412
Johnson KA, Minoshima S, Bohnen NI et al (2013) Appropriate use criteria for amyloid PET: A report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer’s association. J Nucl Med 54(3):476–490
Okamura N, Harada R, Furumoto S et al (2014) Tau PET imaging in Alzheimer’s disease. Curr Neurol Neurosci Rep 14(11):500. doi:10.1007/s11910-014-0500-6
Okamura N, Furumoto S, Fodero-Tavoletti MT et al (2014) Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137(Pt 6):1762–1771. doi:10.1093/brain/awu064
Harada R, Okamura N, Furumoto S et al (2015) [(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 42(7):1052–1061. doi:10.1007/s00259-015-3035-4
Okamura N, Furumoto S, Harada R et al (2014) Characterization of [18F]THK-5351, a novel PET tracer for imaging tau pathology in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 41:S260
Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34:457–468
Chien DT, Szardenings AK, Bahri S et al (2014) Early clinical PET imaging results with the Novel PHF-Tau radioligand [F18]-T808. J Alzheimers Dis 38:171–184
Maruyama M, Shimada H, Suhara T et al (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79:1094–1108
Jacobs AH, Tavitian B; INMiND consortium (2012) Noninvasive molecular imaging of neuroinflammation. J Cereb Blood Flow Metab 32(7):1393–1415. doi:10.1038/jcbfm.2012.53
Cagnin A, Brooks DJ, Kennedy AM et al (2001) In-vivo measurement of activated microglia in dementia. Lancet 358(9280):461–467
Edison P, Archer HA, Gerhard A et al (2008) Microglia, amyloid, and cognition in Alzheimer’s disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 32(3):412–419. doi:10.1016/j.nbd.2008.08.001
Kreisl WC, Lyoo CH, McGwier M et al (2013) Biomarkers Consortium PET Radioligand Project Team. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain 136(Pt 7):2228–2238. doi:10.1093/brain/awt145
Wiley CA, Lopresti BJ, Venneti S et al (2009) Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 66(1):60–67
Fowler JS, Logan J, Volkow ND, Wang GJ (2005) Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Mol Imaging Biol 7:377–387
Saura J, Bleuel Z, Ulrich J et al (1996) Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience 70:755–774
Carter SF, Schöll M, Almkvist O et al (2012) Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 53(1):37–46
Villemagne VL, Burnham S, Bourgeat P et al (2013) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12(4):357–367
Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13(6):614–629
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269
Morris JC, Blennow K, Froelich L et al (2014) Harmonized diagnostic criteria for Alzheimer’s disease: recommendations. J Intern Med 275(3):204–213. doi:10.1111/joim.12199
Prestia A, Caroli A, Wade SK et al (2015) Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimers Dement 11(10):1191–1201, pii: S1552-5260(14)02890-8
Vos SJ, Verhey F, Frölich L et al (2015) Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain 138(Pt 5):1327–1338. doi:10.1093/brain/awv029
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Rinne, J.O. (2016). PET Imaging as a Diagnostic Tool in Alzheimer’s Disease. In: Ingelsson, M., Lannfelt, L. (eds) Immunotherapy and Biomarkers in Neurodegenerative Disorders. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3560-4_13
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3560-4_13
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3558-1
Online ISBN: 978-1-4939-3560-4
eBook Packages: Springer Protocols